

340B Drug Pricing Program

Protecting Patients and Health Care Providers

Vote **YES**
on SB 25-071
and **NO**
on SB 25-124

What is 340B?

The legislative intent of the 340B Drug Pricing Program, created by Congress more than 30 years ago, is to “stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” It protects patients and health care providers from high drug costs – all at no additional cost to taxpayers.

This year, legislators face a crucial choice that will impact the future of the 340B Drug Pricing Program in Colorado and the benefits it provides to patients.

Vote **YES**
on SB 25-071

Vote **NO**
on SB 25-124

Keeps money in Colorado:

- Stops the national effort from Big Pharma to weaken 340B
- Keeps drug companies from restricting the benefits to hospitals and their communities
- Maintains important benefits that improve access to care, reduce costs, and help keep local hospitals and health centers viable

Increases transparency:

- Requires annual reporting of a hospital’s aggregate 340B benefit
- Details how the program money is spent by 340B entities to help their patients and communities
- Ensures that 340B savings continue to be used for patient care

Takes needed funds from Colorado:

- Threatens the \$700 million currently available for charity care and health care services
- Limits access for low-income patients to lifesaving, highly specialized care

Gives money to Big Pharma:

- Places reporting requirements on care providers that are incredibly burdensome
- Will make participation in 340B program untenable
- With fewer communities benefitting from 340B, all savings go back to Big Pharma’s pockets

FOR MORE INFORMATION:

Contact Saskia Young, CHA VP of legislative affairs, at Saskia.Young@cha.com